ストックスクリーナーアプリを入手
9.87
1.92%
0.21
前日終値:
$9.66
開ける：
$9.67
24時間の取引高:
29,976
Relative Volume:
0.02
時価総額：
$956.18M
収益：
-
当期純損益:
$-119.87M
株価収益率:
-5.453
EPS:
-1.81
ネットキャッシュフロー:
$-109.90M
1週間 パフォーマンス:
+7.01%
1か月 パフォーマンス:
-10.58%
6か月 パフォーマンス:
+25.41%
1年 パフォーマンス:
+5.86%
1日の値動き範囲:
$9.67
$9.8688
1週間の範囲:
$9.195
$10.31
52週間の値動き範囲:
$3.8951
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
名前
Oric Pharmaceuticals Inc
セクター
電話
(650) 388-5600
住所
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
ORIC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
9.845 | 938.21M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.13 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
582.87 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.24 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
658.67 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.12 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2024-10-31 | 開始されました | Wells Fargo | Overweight |
| 2024-09-06 | 開始されました | Stifel | Buy |
| 2024-02-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 開始されました | Wedbush | Outperform |
| 2023-03-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-16 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 再開されました | Oppenheimer | Perform |
| 2022-04-04 | アップグレード | Citigroup | Neutral → Buy |
| 2022-03-25 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-03-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-03-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-07-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-01-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-08-13 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-06 | アップグレード | Citigroup | Neutral → Buy |
| 2020-08-03 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-19 | 開始されました | Citigroup | Neutral |
| 2020-05-19 | 開始されました | Guggenheim | Buy |
| 2020-05-19 | 開始されました | JP Morgan | Overweight |
| 2020-05-19 | 開始されました | Jefferies | Buy |
すべてを表示
Oric Pharmaceuticals Inc (ORIC) 最新ニュース
Volume spikes in ORIC Pharmaceuticals Inc. stock – what they mean2025 Biggest Moves & Verified Entry Point Detection - Newser
Equities Analysts Offer Predictions for ORIC Q3 Earnings - Defense World
Oric Pharmaceuticals (NASDAQ:ORIC) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
How to manage a losing position in ORIC Pharmaceuticals Inc.Quarterly Profit Report & Expert Approved Momentum Trade Ideas - Newser
Visualizing ORIC Pharmaceuticals Inc. stock with heatmaps2025 Technical Overview & Daily Stock Trend Watchlist - Newser
Signal strength of ORIC Pharmaceuticals Inc. stock in tech scannersWeekly Trend Summary & Free Technical Confirmation Trade Alerts - Newser
Visual trend scoring systems applied to ORIC Pharmaceuticals Inc.Trade Exit Report & Growth Focused Entry Reports - Newser
Wedbush Predicts Weaker Earnings for Oric Pharmaceuticals - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded to Hold at Zacks Research - MarketBeat
Can ORIC Pharmaceuticals Inc. rally from current levels2025 Year in Review & Growth Oriented Trade Recommendations - Newser
What data driven models say about ORIC Pharmaceuticals Inc.’s futureJuly 2025 Catalysts & Consistent Income Trade Recommendations - Newser
Will ORIC Pharmaceuticals Inc. see short term momentumDividend Hike & Safe Capital Growth Tips - Newser
Market reaction to ORIC Pharmaceuticals Inc.’s recent newsWeekly Market Report & Fast Moving Stock Watchlists - Newser
Can volume confirm reversal in ORIC Pharmaceuticals Inc.2025 Sector Review & Risk Adjusted Buy/Sell Alerts - Newser
Oric Pharmaceuticals Faces Potential Setbacks Amid Competitors’ Clinical Trials - MSN
ORIC Pharmaceuticals Inc.’s volatility index tracking explainedWeekly Trade Review & Real-Time Volume Analysis - Newser
Will a bounce in ORIC Pharmaceuticals Inc. offer an exitTrend Reversal & Reliable Entry Point Alerts - Newser
Chart Analysts Warn of Resistance Near ORIC Pharmaceuticals Inc. PriceJuly 2025 Levels & Community Verified Trade Signals - newsyoung.net
JPMorgan Chase & Co. Has Lowered Expectations for Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Given New $19.00 Price Target at HC Wainwright - MarketBeat
Q3 EPS Estimates for Oric Pharmaceuticals Reduced by Wedbush - Defense World
Will ORIC Pharmaceuticals Inc. continue its uptrend2025 Price Momentum & Community Driven Trade Alerts - Newser
HC Wainwright Lowers Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $19.00 - Defense World
Layoff Tracker: Bausch Health Closes California Site, Cuts 49 Employees - BioSpace
Oric Pharmaceuticals: Promising Future with Key Trials and Financial Stability Underpinning Buy Rating - TipRanks
Oric Pharmaceuticals' (ORIC) Buy Rating Reiterated at Guggenheim - MarketBeat
XTX Topco Ltd Cuts Stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Oric Pharmaceuticals (NASDAQ:ORIC) Given New $17.00 Price Target at JPMorgan Chase & Co. - Defense World
Guggenheim Reaffirms “Buy” Rating for Oric Pharmaceuticals (NASDAQ:ORIC) - Defense World
What makes ORIC Pharmaceuticals Inc. stock price move sharplyEarnings Recap Summary & Fast Entry Momentum Trade Alerts - Newser
A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $12 to $23 - 富途牛牛
How to forecast ORIC Pharmaceuticals Inc. trends using time series2025 Trade Ideas & AI Powered Market Entry Strategies - Newser
Jefferies Reiterates Buy Rating on Oric Pharmaceuticals with $23 Price Target. - AInvest
Guggenheim Reaffirms Buy Rating for ORIC Pharmaceuticals with $18 Target Price. - AInvest
Contineum Therapeutics shares fall 1.04% intraday after ORIC Pharmaceuticals reports positive clinical data and financing activity. - AInvest
Moving Average Trends for ORIC Pharmaceuticals Inc. Stock: What They IndicateWeekly Risk Report & Free Risk Controlled Daily Trade Plans - Newser
Guggenheim Reiterates Buy Rating for ORIC Pharmaceuticals | ORIC Stock News - GuruFocus
Guggenheim Keeps Buy Rating, Raises PT for ORIC Pharmaceuticals to $18. - AInvest
ORIC Pharmaceuticals stock price target raised to $23 by Jefferies - Investing.com Canada
Oric Pharmaceuticals Focuses on Lead Clinical Programs - MSN
ORIC Pharmaceuticals Inc. stock momentum explainedEarnings Miss & High Return Trade Opportunity Guides - Newser
Oppenheimer Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Using flow based indicators on ORIC Pharmaceuticals Inc.Real-Time Investment Signal Forecast with AI - Newser
Using economic indicators to assess ORIC Pharmaceuticals Inc. potentialStrategy Playbook for Risk Controlled Trades - Newser
ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates - GlobeNewswire
ORIC Pharmaceuticals Trims Costs To Back Key Drug Trials - Finimize
Vivo Capital LLC Buys 802,632 Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Oric Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Oric Pharmaceuticals reports Q2 EPS (47c), consensus (44c) - TipRanks
ORIC Pharmaceuticals reports Q2 net loss of $36.4 mln - MarketScreener
Oric Pharmaceuticals Inc (ORIC) 財務データ
収益
当期純利益
現金流量
EPS
Oric Pharmaceuticals Inc (ORIC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Jun 24 '25 |
Sale |
10.50 |
32,466 |
341,039 |
68,317 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 23 '25 |
Sale |
10.00 |
1,034 |
10,344 |
100,783 |
| You Angie | Director |
Jun 20 '25 |
Buy |
9.39 |
26,597 |
249,669 |
26,597 |
| You Angie | Director |
Jun 23 '25 |
Buy |
9.43 |
1,403 |
13,230 |
28,000 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 12 '25 |
Sale |
10.00 |
300 |
3,000 |
101,817 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 11 '25 |
Sale |
10.01 |
2,976 |
29,777 |
102,117 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 10 '25 |
Sale |
10.00 |
324 |
3,240 |
105,093 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 06 '25 |
Sale |
10.01 |
2,600 |
26,021 |
104,164 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 09 '25 |
Sale |
10.00 |
300 |
3,000 |
103,864 |
0.14%
0.30%
大文字化:
|
ボリューム (24 時間):